Abstract
A recent analysis of the Eastern Cooperative Oncology Group E1900 study by Gonen et al. [1] showed that the presence of CD25 at diagnosis identifies AML patients with shorter relapse free survival (RFS) as well as overall survival (OS). A smaller group of AML patients previously analyzed by the HOVON group showed that CD25 expression is associated with shortened RFS and OS [2]. Both studies compared induction chemotherapy with standard versus escalated anthracycline dose followed by Stem Cell Transplantation (SCT) or high dose cytarabine (HiDAC). Gonen et al. also described our recent related analysis [3]. We have performed additional analyses of our cohort and would like to highlight differences from the two aforementioned studies [4].
Highlights
A recent analysis of the Eastern Cooperative Oncology Group E1900 study by Gönen et al [1] showed that the presence of CD25 at diagnosis identifies AML patients with shorter relapse free survival (RFS) as well as overall survival (OS)
A smaller group of AML patients previously analyzed by the HOVON group showed that CD25 expression is associated with shortened RFS and OS [2]
We did not observe a difference in OS between CD25 positive versus CD25 negative patients (Table 1), but we noted a markedly increased cumulative incidence of relapse in CD25 positive patients (p=0.0012, Table 1)
Summary
A recent analysis of the Eastern Cooperative Oncology Group E1900 study by Gönen et al [1] showed that the presence of CD25 at diagnosis identifies AML patients with shorter relapse free survival (RFS) as well as overall survival (OS). Both studies compared induction chemotherapy with standard versus escalated anthracycline dose followed by Stem Cell Transplantation (SCT) or high dose cytarabine (HiDAC). Many CD25 positive patients carried Flt3ITD mutation which, in preclinical models, confers sensitivity to cytarabine, but anthracyclines do not seem to add much activity [5].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Hematology & Thromboembolic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
